Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Accured Expenses (2020 - 2025)

Maravai Lifesciences Holdings has reported Change in Accured Expenses over the past 6 years, most recently at -$13.5 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$13.5 million for Q4 2025, down 764.07% from a year ago — trailing twelve months through Dec 2025 was -$4.6 million (up 80.51% YoY), and the annual figure for FY2025 was -$4.6 million, up 80.51%.
  • Change in Accured Expenses for Q4 2025 was -$13.5 million at Maravai Lifesciences Holdings, down from $1.5 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for MRVI hit a ceiling of $24.2 million in Q1 2023 and a floor of -$24.1 million in Q1 2024.
  • Median Change in Accured Expenses over the past 5 years was $1.5 million (2025), compared with a mean of -$398100.0.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 882.5% in 2022 and later crashed 870.77% in 2023.
  • Maravai Lifesciences Holdings' Change in Accured Expenses stood at $7.5 million in 2021, then tumbled by 175.11% to -$5.6 million in 2022, then surged by 213.99% to $6.4 million in 2023, then plummeted by 124.45% to -$1.6 million in 2024, then tumbled by 764.07% to -$13.5 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$13.5 million (Q4 2025), $1.5 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.